- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
UC Davis Comprehensive Cancer Center | Strategic Alliance Partners
UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.
Latest from UC Davis Comprehensive Cancer Center
Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship
December 04, 2025
Video
R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.
Dr Randall on the Importance of Addressing Socioeconomic Disparities to Improve Sarcoma Survivorship
November 27, 2025
Video
R. Lor Randall, MD, FACS, discusses the potential implications of research into how socioeconomic disparities and cancer biology impact long-term outcomes in pediatric sarcoma.
Dr Randall on the Goals and Methods of Prospective Research on Disparities in Sarcoma Survivorship
November 20, 2025
Video
R. Lor Randall, MD, FACS, outlines the aims and phases of a prospective study evaluating outcome disparities in pediatric sarcoma survivorship care.
Dr Randall on the Need for Precision Survivorship Care in Pediatric and AYA Sarcoma
November 13, 2025
Video
R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.
Advances in EGFR+, HER2-Mutant, and CNS-Involved NSCLC Dominate Discussion After ESMO 2025
October 30, 2025
Article
Experts highlight pivotal data in EGFR- and HER2-mutant NSCLC from the 2025 ESMO Congress, including updates on ADCs, TKIs, and real-world outcomes in LMD.
Dr Randall on Incorporating Ultrasound STS Surveillance Into Clinical Practice
October 30, 2025
Video
R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.
Dr Randall on the Potential Role of Ultrasound in Soft Tissue Sarcoma Surveillance
October 23, 2025
Video
R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.
Dr Randall on the Diagnostic Accuracy and Cost Effectiveness of MRI vs Ultrasound in STS
October 16, 2025
Video
R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.
Genetic “Trojan Horse” Selectively Kills Cancer Cells Linked to Kaposi’s Sarcoma
October 15, 2025
Article
Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue
Dr Randall on the Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance
October 09, 2025
Video
R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.
MRI and Ultrasound May Be Best Used in Tandem for Surveillance Imaging in Soft Tissue Sarcoma
September 12, 2025
Article
Ultrasound is cheaper, faster, and is widely available compared with MRI, but is it enough to displace the gold standard imaging tool?
Molecular Research With Benign, Self-Limiting Bone Lesion May Unlock New Treatment Avenues for RAS/MAPK-Activated Tumors
August 29, 2025
Article
R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.
Prospective Cohort Study Highlights QOL Benefits of Surgery for Bone Metastases in Advanced Cancer
July 24, 2025
Article
R. Lor Randall, MD, FACS, discusses when to intervene prophylactically in patients with advanced cancer and skeletal metastases.
EXPLORER Shrinks the Time it Takes for Imaging to Spot Cancer
July 08, 2025
Article
Cancer parametric PET imaging with radioactive tracers is reduced from an hour to 20 minutes
Dr Nagasaka on the Importance of Taletrectinib for the ROS1+ NSCLC Treatment Paradigm
June 27, 2025
Video
Misako Nagasaka, MD, PhD, discussed the clinical significance of the FDA approval of taletrectinib in ROS1-positive NSCLC.
Wheat Germ May Boost Immunotherapy in Cancer Patients
June 24, 2025
Article
A clinical trial is testing an extract that could unlock the body’s natural ability to fight cancer.
Biomarkers Hold Clue in Treating Aggressive Prostate Cancer
June 10, 2025
Article
Clinical trial tests new treatment approach, offers hope for personalized therapies.
Orthopedic Oncology Experts Shape Global Consensus on Chondrosarcoma Management
April 19, 2025
Article
R. Lor Randall, MD, FACS, discusses the importance of orthopedic oncology consensus meetings and the need for agreement about certain surgical practices.
Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control
March 21, 2025
Article
R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.
Vimseltinib Stands Out as An Alternative to Surgery for Select Patients With Diffuse TGCT
March 06, 2025
Article
R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.